First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid TumoursBusiness Wire • 07/10/23
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness Wire • 06/06/23
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS EuropeBusiness Wire • 05/22/23
Exscientia's AI-Powered Drug Discovery Platform Is The Future Of Precision MedicineSeeking Alpha • 05/18/23
Professor Andrew L. Hopkins elected Fellow of the Academy of Medical SciencesBusiness Wire • 05/17/23
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical StageBusiness Wire • 05/15/23
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of DirectorsBusiness Wire • 05/03/23
Data Presented at AACR 2023 Highlights Exscientia's Clinical and Preclinical DevelopmentBusiness Wire • 04/19/23
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACRBusiness Wire • 03/15/23
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine PlatformBusiness Wire • 03/07/23